CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
− To identify and address, through clinical trial and translational research, the disease burden associated with head and neck malignancies in Canada.
− To identify clinical and research opportunities within the current Head and Neck Disease Site Committee portfolio.
− To integrate current knowledge regarding tumour biology in clinical trial concept development and conduct.
− To apply new clinical trial methodologies to head and neck studies.
− To provide a learning environment supportive of all (new) investigators.

8:00 am Welcome

Ongoing Trials

8:05 am  HN.9 - Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC).  
A Spreafico

8:25 am  HN.10 - A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma.  
S Bratman

8:45 am  HNC.2 (NRG-HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin.  
E Winquist
## Trials Under Consideration

**9:05 am**  
EA3163 Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)  
J de Almeida/A Nichols

**9:25 am**  
NRG-HN005 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer  
J Waldron

**9:45 am**  
Break

**10:00 am**  
PRO-ACTIVE: Comparing the Effectiveness of Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer  
J Ringash

## New Proposals

**10:20 am**  
Novel Oral RTK Inhibitor (Sitravatinib) in Combination with Nivolumab as Concomitant and Maintenance Therapy for HPV Negative LAHNSCC  
K Taylor

**10:40 am**  
Neoadjuvant RT +/- Immunotherapy for Squamous Cell Cancer of the Head and Neck  
M Gaudet

**11:00 am**  
Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): A Randomized Multicentric Bayesian Phase II Trial  
H Bahig

**11:20 am**  
Stereotactic boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer (SHORT-OPC) Trial: A Randomized Multicentric Bayesian Phase I-II Trial  
H Bahig

**11:40 am**  
Terms of Reference: Head and Neck Committee  
W Parulekar

**12:40**  
SPECT guided management of the Contralateral Neck in Lateralized Oropharyngeal Carcinoma: A Phase II Randomized Controlled Trial  
J de Almeida/A Hosni

**1:00 pm**  
PM.1 - Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial  
W Parulekar

**1:15 pm**  
Other Business

**2:00 pm**  
Meeting Adjourned